Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply

Hyeyeon Hong, Jonggi Choi

Clin Mol Hepatol. 2024;30(2):272-273. Published online February 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0123

View: 739 Download: 60

Original Article

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi

Clin Mol Hepatol. 2024;30(1):49-63. Published online November 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0328

View: 2068 Download: 179 Crossref: 2

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 4920 Download: 277 Web of Science: 18 Crossref: 20

Editorial

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Hung-Yao Lin, Tai-Chung Tseng

Clin Mol Hepatol. 2022;28(2):181-182. Published online February 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0028

View: 3868 Download: 116 Web of Science: 3 Crossref: 3

Review

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim

Clin Mol Hepatol. 2021;27(3):402-412. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0179

View: 5852 Download: 252 Web of Science: 32 Crossref: 30

Original Article

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn

Clin Mol Hepatol. 2020;26(3):352-363. Published online May 28, 2020

DOI: https://doi.org/10.3350/cmh.2019.0044n

View: 4777 Download: 181 Web of Science: 3 Crossref: 5

Editorial

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0099

View: 4876 Download: 119 Crossref: 2

Review

Unmet need in chronic hepatitis B management

Lilian Yan Liang, Grace Lai-Hung Wong

Clin Mol Hepatol. 2019;25(2):172-180. Published online February 12, 2019

DOI: https://doi.org/10.3350/cmh.2018.0106

View: 9322 Download: 394 Web of Science: 43 Crossref: 45

Original Article

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin

Clin Mol Hepatol. 2017;23(3):230-238. Published online June 30, 2017

DOI: https://doi.org/10.3350/cmh.2017.0003

View: 9375 Download: 164 Web of Science: 11 Crossref: 13

Editorial

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(3):219-221. Published online September 19, 2017

DOI: https://doi.org/10.3350/cmh.2017.0045

View: 7630 Download: 152 Web of Science: 1 Crossref: 2

Original Article

Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B

Hee Yeon Seo, Han Ah Lee, Soon Young Ko, Joon Ho Wang, Jeong Han Kim, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2017;23(2):154-159. Published online May 8, 2017

DOI: https://doi.org/10.3350/cmh.2016.0067

View: 7368 Download: 170 Web of Science: 7 Crossref: 7

Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients

Goh Eun Chung, Eun Ju Cho, Jeong-Hoon Lee, Jeong-ju Yoo, Minjong Lee, Yuri Cho, Dong Hyeon Lee, Hwi Young Kim, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim

Clin Mol Hepatol. 2017;23(1):66-73. Published online February 14, 2017

DOI: https://doi.org/10.3350/cmh.2016.0060

View: 9822 Download: 167 Web of Science: 12 Crossref: 11

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)

Hye Won Lee, Jun Yong Park, Beom Kyung Kim, Moon Young Kim, Jung Il Lee, Young Suk Kim, Ki Tae Yoon, Kwang-Hyub Han, Sang Hoon Ahn

Clin Mol Hepatol. 2016;22(4):443-449. Published online November 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0037

View: 9761 Download: 158 Web of Science: 10 Crossref: 8

Editorial

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol. 2016;22(4):439-442. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0108

View: 7473 Download: 111 Web of Science: 1 Crossref: 1

Case Report

Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases

Hyeki Cho, Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Kook-Hwan Oh, Kyoungbun Lee, Syifa Mustika, Jung-Hwan Yoon, Yoon Jun Kim

Clin Mol Hepatol. 2016;22(2):286-291. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2015.0066

View: 10165 Download: 175 Web of Science: 11 Crossref: 13

Original Article

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy

Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon

Clin Mol Hepatol. 2016;22(2):241-249. Published online June 15, 2016

DOI: https://doi.org/10.3350/cmh.2015.0053

View: 9757 Download: 138 Web of Science: 4 Crossref: 4

Editorial

Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?

Hyung Joon Yim

Clin Mol Hepatol. 2016;22(2):238-240. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0103

View: 8245 Download: 93 Web of Science: 1 Crossref: 1

Original Article

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B

Chan Ho Park, Seok Won Jung, Jung Woo Shin, Mi Ae Bae, Yoon Im Lee, Yong Tae Park, Hwa Sik Chung, Neung Hwa Park

Clin Mol Hepatol. 2016;22(1):152-159. Published online March 28, 2016

DOI: https://doi.org/10.3350/cmh.2016.22.1.152

View: 9383 Download: 94

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy

Jung Gil Park, Soo Young Park

Clin Mol Hepatol. 2015;21(3):242-248. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.242

View: 8048 Download: 84 Web of Science: 5 Crossref: 3

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients

Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa

Clin Mol Hepatol. 2015;21(1):41-48. Published online March 25, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.1.41

View: 8302 Download: 82 Web of Science: 14 Crossref: 11

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort

Sung Soo Ahn, Young Eun Chon, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park

Clin Mol Hepatol. 2014;20(3):261-266. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.261

View: 9113 Download: 78 Web of Science: 13 Crossref: 10

1 |

Viewed By 5394	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5361	MAFLD: How is it different from NAFLD?
Viewed By 5244	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3924	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3900	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search